| abstract |
The present invention relates to the field of genetically engineered protein drugs, more specifically, relates to recombinant targeting fusion protein TRAIL-μPA-GST and its anti-tumor application, which is related to urokinase-type plasminogen activator (u-PA) and tumor necrosis factor Apoptosis-inducing ligand (TRAIL) and glutathione S-transferase (GST) consisting of the amino acid sequence of SEQ ID NO.2, expression-type recombinants containing the genes, engineering bacteria containing the expression-type recombinants, composed of The targeting fusion protein TRAIL-μPA-GST expressed and isolated by this engineering bacterium and the specific killing effect of the targeting fusion protein on a type of colon cancer malignant tumor cells, the recombinant targeting fusion protein TRAIL-μPA-GST of this technical scheme Compared with the prototype TRAIL, the recombinant fusion protein TRAIL-μPA-GST of the present invention has a better application prospect. |